Diabetes Drug Tradjenta Associated With Bullous Pemphigoid, A Chronic Blistering Skin Condition

Bullous Pemphigoid (BP) Is An Auto-Immune Skin Disease Which Can Be Fatal, Particularly In Patients Who Are Debilitated   (Posted by Tom Lamb at DrugInjuryWatch.com)   Three relatively new medical studies add weight to an emerging drug safety issue involving Tradjenta (linagliptin), which is part of the dipeptidyl peptidase 4 (DPP-4) inhibitors class of type 2 diabetes drugs. Before getting to the recent medical journal articles which seem to show that an increased risk of bullous pemphigoid (BP) is a side effect associated with Tradjenta, we point out that at least three other diabetes drugs also contain linagliptin, which is the active ingredient in Tradjenta: Glyxambi (empagliflozin and linagliptin) Jentadueto (linagliptin and metformin hydrochloride) Jentadueto XR (linagliptin and metformin hydrochloride) The first medical journal article, "Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes", provides…

Read more detail on Recent Products Liability posts –

This entry was posted in Products Liability and tagged , , , , , , , , , . Bookmark the permalink.

Leave a Reply